SciSparc (SPRC) announced that its collaboration with Clearmind Medicine (CMND) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines and Palmitoylethanolamide. This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease. This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind completes site initiation for CMND-100 trial
- Clearmind Medicine completes initiation at TASMC for Phase I/IIa trial
- Psychedelic: Clearmind expands trial for Alcohol Use Disorder
- Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results
- Clearmind Medicine announces IRB approval for Phase 1/2a trial for AUD